Roth starts Intellipharmaceutics at buy

Roth Capital Partners has initiated coverage of Intellipharmaceutics (NASDAQ:IPCI; TSX:I) with a “buy” rating and 12-month price target of $5.25, saying the emerging generics company could launch four new products in the coming 12-to-18 months. “We believe that this momentum could unlock value for this under covered stock,” writes analyst Scott Henry. The stock closed [...]

Intellipharmaceutics and Par amend Focalin XR pact

Intellipharmaceutics International (NADAQ:IPCI; TSX:I) and Par Pharmaceutical have added the development and commercialization of additional strengths of generic Focalin XR for the U.S. market to their existing agreement, which applied to the development and commercialization of the 5, 10, 15 and 20 mg strengths of generic Focalin XR. Five strengths (5, 10, 15, 20 and 30 mg) [...]

Intellipharmaceutics hires Doll to commercialize drugs

Intellipharmaceutics International (NASDAQ:IPCI; TSX:I) has retained Doll Consulting and its principal, David Doll, to assist the company with the commercialization of products in its controlled-release generic drug and NDA portfolios. “We now have four products filed with the FDA for the purpose of obtaining regulatory approval in the U.S. – ANDA’s for Focalin XR, Effexor [...]

Neil resigns as CFO of Intellipharmaceutics

Graham Neil has resigned as CFO of Intellipharmaceutics International (NASDAQ:IPCI; TSX:I), effective Nov. 26, to pursue other business opportunities. President and COO Dr. Amina Odidi has been named acting CFO, pending the appointment of a permanent replacement. She had previously served as CFO for several years until October, 2009.

You asked a CEO

Four weeks ago, we asked you what’s on your mind. Specifically, what would you like to “Ask a CEO?”  Frankly, we were heartened and surprised by your response. So as promised, this week’s Feature, which coincides with the first anniversary of biotuesdays.com’s launch, is a rundown of the questions and the answers we received. We [...]

Intellipharmaceutics CEO moulded at Biovail U

Fifteen years ago, Dr. Isa Odidi performed magic as CSO of Biovail (NYSE:BVF; TSX:BVF), developing several blockbuster generics, including hard-to-manufacture copies of Bayer’s Adalat CC, Pfizer’s Procardia XL and Novartis’ Voltaren XR. “We have the same style here at Intellipharmaceutics (NASDAQ:IPCI; TSX:I) as we had at Biovail,” Dr. Odidi says in an exclusive interview with [...]

Intellipharmaceutics files ANDA for generic Protonix

Intellipharmaceutics International (NASDAQ:IPCI; TSX:I) has filed an ANDA with the FDA for a generic of Protonix (delayed-release pantoprazole sodium), which inhibits gastric acid secretion and is prescribed for conditions such as stomach ulcers associated with gastroesophageal reflux disease and hypersecretory conditions including Zollinger-Ellison syndrome. Sales of pantoprazole sodium delayed-release tablets in the U.S. were about [...]

Intellipharmaceutics advances abuse-deterrent oxycodone

Intellipharmaceutics International (NASDAQ:IPCI; TSX:I) has taken delivery of and fully qualified its primary manufacturing equipment for the manufacture of oxycodone CR, an abuse-deterrent formulation of controlled-release oxycodone hydrochloride. The company also said it has begun making clinical batches of the drug for Phase 1 studies and to establish a clinical program in cooperation with the [...]

FDA accepts Intellipharmaceutics ANDA

The FDA has accepted an abbreviated new drug application from Intellipharmaceutics International (NASDAQ:IPCI; TSX:I) for a generic version of the antidepressant Effexor XR. “This product was entirely developed and filed using our in-house laboratory, manufacturing and regulatory resources,” CEO Dr. Isa Odidi said in a statement.  “The acceptance of this filing also fulfills one of [...]

Intellipharmaceutics in patent settlement for generic Focalin XR

Intellipharmaceutics International (TSX:I; NASDAQ:IPCI) announced patent settlements over a generic version of the attention deficit hyperactivity disorder drug Focalin XR in the U.S. In a statement, the company said Novartis Pharmaceuticals (NYSE:NVS) and Celgene (NASDAQ:CELQ) have settled their patent suit in the U.S. District Court for the District of New Jersey.  Also, Elan Pharma International [...]